SimplicityCV and Renal Safety Efficacy Adverse events Previous Next Simple. Every day. Linagliptin (Trajenta®) simplicity and convenience 29/12/2022 | Author: Boehringer Ingelheim Document ID: PC-PH-104444 Simplicity With CARMELINA®, linagliptin demonstrated a long-term cardiovascular safety profile in patients with T2D and showed no increase in risk of hospitalisation for heart failure Trajenta Recorded Webinar - Per Henrik Groop Limited to Kidney Video - Roger Chen Simplicity Believer Video - Ted Wu Simplicity of Trajenta Relevance of Linagliptin in 2021 Limited to kidney video by Dr. Peter Lin Limited to kidney video by Prof. Roger Chen Ask the Expert: Prof O'Brien on Broad Range of Patients Not All DPP4i are the Same TSC||Key Results of the CARMELINA Trial TSC||CARMELINA Asian Sub-group Analysis What are the key results of CARMELINA/CAROLINA and why is it unique vs other DPP4i CVOTs? TSC||The Simplicity of Linagliptin (Trajenta) Linagliptin (Trajenta®) simplicity and convenience RELATED CONTENT Read more 02:00 Linagliptin (Trajenta®) simplicity and convenience Watch now Opens in new tab Home Metabolic Linagliptin Simplicity Linagliptin (Trajenta®) simplicity and convenience